


#5 1648



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Art Unit	
Examiner Name	
Attorney Docket Number	015280-400300US

Total Number of Pages in This Submission

6

ENCLOSURES (Check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement - "Transmittal of Signed IDS"
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Jean M. Lockyer, Ph.D.	Reg. No. 44,879
Signature		
Date	April 14, 2003	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: April 14, 2003

Typed or printed

Malinda C. Dagit

Signature

Date

14 April 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APR 23 2003

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-400300US
Client Reference No.: E-212-99/2

Assistant Commissioner for Patents
Washington, D.C. 20231

On 14 April 2003

TOWNSEND and TOWNSEND and CREW LLP

Malinda Bogert



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Genoveffa Franchini, Zdenek Hel,
Gene Shearer, James Tartaglia and
Janos Nacsá

Application No.: 10/048,072

Filed: January 25, 2002

For: IMMUNOTHERAPY IN HIV
INFECTED PERSONS USING
VACCINES AFTER MULTI-DRUG
TREATMENT

Examiner:

Art Unit:

TRANSMITTAL OF
SIGNED VERSION OF IDS

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants' letter transmitting the IDS mailed to the Patent Office March 10, 2003 was inadvertently not signed. We therefore enclose a signed copy of the letter along with copies of the forms PTO/SB/08A and PTO/SB/08B included with the March 10, 2003 submission. We have not submitted duplicate copies of the references as we believe that they are in the file. However, if duplicate copies are required, we will provide the copies.

Respectfully submitted,

Jean M. Lockyer
Jean M. Lockyer, Ph.D.
Reg. No. 44,879

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 015280-400300US
Client Reference No.: E-212-99/2


#5

On 14 April 2003

TOWNSEND and TOWNSEND and CREW LLP

Melinda C. O'Neil

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



TECH CENTER 1600/2900

APR 23 2003

RECEIVED

In re application of:

Genoveffa Franchini, Zdenek Hel,
Gene Shearer, James Tartaglia and
Janos Nacsa

Application No.: 10/048,072

Filed: January 25, 2002

For: IMMUNOTHERAPY IN HIV
INFECTED PERSONS USING
VACCINES AFTER MULTI-DRUG
TREATMENT

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed, with the exception of those references cited in the parent PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom..


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:mcd
Unsaved Document

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231**



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B-110

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa, et. al.
Art Unit	
Examiner Name	
Attorney Docket Number	015280-400300US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AI	J. Benson <i>et al.</i> , "Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIV _{mac251} : Dependence on Route of Challenge Exposure," <i>Journal of Virology</i> (May 1998) 72(5): 4170-4182.	
	AJ	M. John <i>et al.</i> , "Control of HIV Replication by Cytotoxic T-lymphocyte Responses," <i>J. HIV Therapy</i> (1999) 4(4): 91-87	
	AK	F. Gotch <i>et al.</i> , "Therapeutic Vaccines in HIV 1 Infection," <i>Immunological Reviews</i> (1999) 170: 173-182	
	AL	R. Macgregor <i>et al.</i> , "First Human Trial of a DNA-based Vaccine for Treatment of HIV1 Infection: Safety and Host Response," <i>J. Inf. Dis.</i> , (1998) 178: 92-100	

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1440061 v1